Clinical Trials
96 trialsA Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI)
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Second Affiliated Hospital of Nanchang University
NIBCUN
Sun Yat-sen University
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Shanghai Chest Hospital
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Georgetown University
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
Prestige Biopharma Limited
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Shanghai Pulmonary Hospital, Shanghai, China
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Samsung Bioepis Co., Ltd.
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Ruijin Hospital
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
BECOME
Hunan Province Tumor Hospital
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
Second Affiliated Hospital of Guangzhou Medical University
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
Second Affiliated Hospital of Guangzhou Medical University
CITRINO
Tesaro, Inc.
PTST_PALBEVA
Lebanese University
NТО-RAS
N.N. Petrov National Medical Research Center of Oncology
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Ultimate
Intergroupe Francophone de Cancerologie Thoracique
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Rutgers, The State University of New Jersey
BELIEF
ETOP IBCSG Partners Foundation
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
SCRI Development Innovations, LLC
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Study of Participants With Advanced Non-Small Cell Lung Cancer
Eli Lilly and Company
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
Guangdong Association of Clinical Trials
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
The Effects of Preoperative Bevacizumab on Perioperative Complications
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Genentech, Inc.
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
SWOG Cancer Research Network
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Psychometric Properties of the EORTC QLQ-LC29
University Hospital Regensburg
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Northwestern University
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
Swiss Cancer Institute